$AZTA

Starr Ephraim purchased $8K of AZTA

Starr Ephraim (SVP, Gen Counsel & Secretary) purchased 335 shares of Azenta, Inc. (AZTA) at $24.17 on 2026-07-31.

Original reporting
SEC EDGAR · Starr Ephraim
Published Aug 4, 2026, 10:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AZTA
Neutral
medium confidence
Mentioned
$AZTA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AZTANeutralLow
01

Why it matters

A single officer open-market purchase is disclosed, but the filing contains no new operational or financial information about Azenta.

02

Market read

Traders may note the insider buy as mild sentiment input, but there is no fundamental catalyst in the text.

03

What to watch

The filing does not state intent, timing rationale, or whether the purchase was part of a broader pattern; the absence of a 10b5-1 plan does not confirm conviction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04, transaction dated 2026-07-31

Background

The article is an SEC Form 4 insider transaction disclosure for Azenta, Inc.

Company-level read

Ticker impact

$AZTANeutralMedium confidence
Context

Azenta disclosed a Form 4 showing SVP General Counsel Starr Ephraim bought 335 shares of AZTA at $24.1676 on 2026-07-31.

Expected impact

Likely limited near-term impact; any effect is sentiment-only unless paired with other company-specific news.

Evidence & confidence

Form 4 insider buys can be informative, but the article provides no accompanying guidance, contract, investigation, or operational change. The transaction size ($8.1k) is small relative to typical market-moving thresholds.

Market effects

No clear sector read-through from a small insider open-market buy.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by personal liquidity needs or diversification rather than a bullish view, especially without a clear linkage to company events.

Key entities

  • Azenta, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Starr Ephraim

    SVP, General Counsel & Secretary who purchased AZTA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZTAMed

Why Azenta (AZTA) Stock Is Down Today

Azenta (AZTA) stock fell 9.1% after CEO John Marotta resigned, with Dr. Martin Madaus appointed interim CEO. The company reaffirmed Q4 2026 revenue guidance but noted a $3M one-time EBITDA reduction. Azenta's stock has been volatile, with a 24.6% drop in July 2025 due to mixed Q4 results. The stock is down 17.4% from its 52-week high.

$AZTAHigh

Why is Azenta stock sliding today?

Azenta (AZTA) stock fell 10.4% after CEO John Marotta resigned. Interim CEO Dr. Martin Madaus was appointed. Q4 adjusted EBITDA will include a $3M consulting charge. Revenue guidance was reaffirmed. The Nasdaq Composite was down 0.7%.

$AZTAMedAI 8/10

Azenta (AZTA) Q3 2026 Earnings Call Transcript

Azenta (AZTA) held its Q3 2026 earnings call. CEO John Marotta said revenue exceeded outlook, profitability improved sequentially, and Multiomics grew year over year, with organic revenue up 9% YoY. The company revised FY2026 guidance to reported revenue of $613M to $618M and adjusted EBITDA of $59M to $62M, citing uneven demand and turnaround progress.

$AZTAMedAI 8/10

Azenta (NASDAQ:AZTA) Reports Upbeat Q2 CY2026

Azenta (NASDAQ:AZTA) reported Q2 CY2026 results. Revenue rose 12% year on year to $161.2 million, exceeding Wall Street estimates by 8%, and non-GAAP EPS was $0.16, 60% above consensus and down from $0.19 a year earlier. Analysts expect full-year EPS to rise from $0.42 to $0.64 over the next 12 months.

$AZTAMed

Azenta, Inc. (AZTA): Results of Operations and Financial Condition

Azenta, Inc. (AZTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026. BURLINGTON, Mass., August 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026. The results of B Medical Systems are r